MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On June1, 2018, Ryan Selhorn resigned as the Chief Financial Officer of the MediciNova, Inc. (the “Company”). Mr.Selhorn had served as the Company’s Chief Financial Officer through a services agreement (the “Services Agreement”) between the Company and the accounting services firm Analytics San Diego LLC (“ Analytics”). Mr.Selhorn previously resigned from Analytics.

Effective June1, 2018, the Board of Directors of the Company appointed Carla Reyes of Analytics to serve as Chief Financial Officer and principal financial officer of the Company. In connection with Ms.Reyes’ appointment as Chief Financial Officer, on the same date, the Company entered into an amendment to the Services Agreement with Analytics for the provision of Ms.Reyes’ services. Under the Services Agreement, as amended, the Company will continue to pay pre-approved hourly rates for the services provided under the Services Agreement. The current term of the Services Agreement, as amended, will expire on March31, 2019, subject to earlier termination according to its terms.

Ms.Reyes, age 46, joined Analytics in May 2018. From August 2013 to May 2018, Ms.Reyes served as Accounting Manager at Rady Children’s Hospital-San Diego, where she was responsible for financial reporting, grants and contracts, and philanthropy accounting. Prior to this, Ms.Reyes served as Senior Manager of Business Processes at Cricket Communications, a wireless service provider, from May 2009 to August 2013. Earlier in her career, Ms.Reyes served in accounting and public reporting roles at SAIC, NextWave and Quest Software. Ms.Reyes received a Bachelor of Accountancy and an MBA from the University of San Diego.

There are no family relationships between Ms.Reyes and any of the Company’s other directors or executive officers, and Ms.Reyes does not have any direct or indirect material interests in any transaction required to be disclosed to Item404(a) of Regulation S-K.


About MEDICINOVA, INC. (NASDAQ:MNOV)

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.

An ad to help with our costs